Vitamin K
Of 4,787 on-market vitamin k products in the January 2026 DSLD dump, the median declared dose is 75 mcg, and 73.3% list Phytonadione / Phylloquinone (Vitamin K1) as the primary form.
Form share
Of 4,439 products with an identifiable primary form, here is the share held by each form of Vitamin K on the market today.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
| Form | Quality tier | n | Share |
|---|---|---|---|
| Phytonadione / Phylloquinone (Vitamin K1) | Tier 1 | 3,255 | 73.3% |
| Menaquinone-7 (MK-7) | Unrated | 1,175 | 26.5% |
| Menaquinone-4 (MK-4) | Unrated | 9 | 0.2% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mcg), among 4,706 products with a disclosed amount, against the RDA of 120.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
- 0.5% of products don't disclose an amount because Vitamin K is declared inside a proprietary blend.
Where does your dose rank?
Enter a per-serving dose (mcg) to see exactly how it compares to the 4,705 on-market vitamin k products with a disclosed amount. The chart above groups doses into deciles; this looks up the exact percentile for one number.
By dosage form
By target group
Top brands
Search interest over time
How often people search for vitamin k on Google, US only, the last 5 years. This is public interest, not DSLD label data — a spike here doesn't necessarily line up with anything on this page, and Google's own index (100 = that term's peak popularity in the chosen window) is relative, not an absolute search-volume count.
Or see this search directly on trends.google.com.
Forms explained
Best-studied form and basis of the AI, but has a much shorter half-life than MK-7 (Schurgers 2007).
Source: Schurgers LJ et al. 2007, Blood 109(8):3279-83, PMID 17158229
Genuinely contested: a much longer half-life than K1, with stable serum levels and 7-8-fold accumulation on prolonged intake (Schurgers 2007), gives much more sustained circulating levels, argued to better serve extrahepatic (bone/vascular) carboxylation, but head-to-head superiority on hard clinical outcomes vs K1 is not firmly established.
Source: Schurgers LJ et al. 2007, PMID 17158229
Used at pharmacological doses (45 mg/day, as menatetrenone) for osteoporosis in Japan; at nutritional doses (420 mcg) MK-4 was not detectable in serum in a head-to-head test against MK-7, so its serum bioavailability appears far lower than MK-7.
Source: Sato T, Schurgers LJ, Uenishi K. 2012, Nutr J 11:93, PMID 23140417
Reference values
- RDA (adult): 120 mcg — Adequate Intake, no RDA established: 120mcg (men); 90mcg (women)
- Tolerable Upper Intake Level (adult): not established — Not established -- no adverse effects convincingly associated with high vitamin K intake
- Studied clinical dose range: ?–180 mcg
- Knapen MHJ et al. 2013, Osteoporos Int 24(9):2499-2507, PMID 23525894 -- 180mcg/day MK-7 x3yr in 244 healthy postmenopausal women decreased the age-related decline in bone mineral content/density at the lumbar spine and femoral neck (total-hip BMD was not significantly different) and improved bone-strength markers vs placebo. No single pinned low-dose comparator RCT was confidently identified -- left null rather than guessed.
- Note: Vitamin K has never had a widely used IU convention on US labels.